InMed Pharmaceuticals

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
Update

17.06.22

InMed Pharmaceuticals — THCV launch expands rare cannabinoids portfolio

Healthcare |
Update

31.05.22

InMed Pharmaceuticals — Health and wellness product launches

Healthcare |
Outlook

03.05.22

InMed Pharmaceuticals — Notable launches of high-value rare cannabinoids

Healthcare |
Update

16.02.22

InMed Pharmaceuticals — Generating commercial sales of CBC and CBT

Visit Website

Sector

Healthcare

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	2.6	(49.4)	(82.2)
Relative	(8.3)	(53.6)	(81.7)
52 week high/low	US$2.4/US$0.4

Financials

Previously published reports can still be accessed via our website.

Y/E Jun	Revenue (US$m)	EBITDA (US$m)	PBT (US$m)	EPS (c)	P/E (x)	P/CF (x)
2020A	0.0	(9.0)	(9.0)	(172.80)	N/A	N/A
2021A	0.0	(9.8)	(10.3)	(153.02)	N/A	N/A
2022E	1.8	(14.6)	(14.8)	(97.62)	N/A	N/A
2023E	10.2	(13.2)	(13.8)	(63.67)	N/A	N/A

Research

Update

Healthcare

17.11.21

InMed Pharmaceuticals — Progress across the business

edison tv

Healthcare

16.11.21

InMed Pharmaceuticals – Introducing the BayMedica Team

Healthcare

edison tv

24.11.21

InMed Pharmaceuticals – introducing the BayMedica Team

edison tv

Healthcare

05.10.21

Webinar: InMed Pharmaceuticals

Update

Healthcare

29.09.21

InMed Pharmaceuticals — NM-755 Phase II about to begin

Update

Healthcare

20.09.21

InMed Pharmaceuticals — Acquiring BayMedica

edison tv

Healthcare

14.09.21

InMed Pharmaceuticals and BayMedica – executive interview

edison tv

Healthcare

05.05.21

Webinar: InMed Pharmaceuticals

Update

Healthcare

22.02.21

InMed Pharmaceuticals — Phase II enrolment to begin in second half

edison tv

Healthcare

03.02.21

InMed Pharmaceuticals – Edison Open House interview

Update

Healthcare

11.01.21

InMed Pharmaceuticals — INM-755 Phase I complete, on to Phase II

edison tv

Healthcare

27.05.20

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

edison tv

Healthcare

28.04.20

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

Update

Healthcare

20.02.20

InMed Pharmaceuticals — INM-755 trial full enrollment expected this quarter

edison tv

Healthcare

23.01.20

Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

Update

Healthcare

22.01.20

InMed Pharmaceuticals — Developing cannabinol (CBN)

Update

Healthcare

18.11.19

InMed Pharmaceuticals — CTA filed on schedule

Update

Healthcare

26.09.19

InMed Pharmaceuticals — INM-755 getting closer to the clinic

edison tv

Healthcare

26.06.19

Executive interview – InMed Pharmaceuticals

Update

Healthcare

22.05.19

InMed Pharmaceuticals — Fiscal Q319 results

Update

Healthcare

14.02.19

InMed Pharmaceuticals — Entering the clinic by the end of the year

Update

Healthcare

20.11.18

InMed Pharmaceuticals — Biosynthesis and INM-750 Progress on Track

Update

Healthcare

20.09.18

InMed Pharmaceuticals — Progressing their programs

Initiation

Healthcare

07.06.18

InMed Pharmaceuticals — Innovating cannabinoids

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Equity strategy and market outlook – January 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

IP Group – executive interview

Take on Trusts – March 2024

Oakley Capital Investments – executive interview

About Edison

About Edison

Careers

InMed Pharmaceuticals (US: INM)

Latest Insights

InMed Pharmaceuticals — THCV launch expands rare cannabinoids portfolio

InMed Pharmaceuticals — Health and wellness product launches

InMed Pharmaceuticals — Notable launches of high-value rare cannabinoids

InMed Pharmaceuticals — Generating commercial sales of CBC and CBT

Sector

Share Price Performance

Financials

Research

InMed Pharmaceuticals — Progress across the business

InMed Pharmaceuticals – Introducing the BayMedica Team

InMed Pharmaceuticals – introducing the BayMedica Team

Webinar: InMed Pharmaceuticals

InMed Pharmaceuticals — NM-755 Phase II about to begin

InMed Pharmaceuticals — Acquiring BayMedica

InMed Pharmaceuticals and BayMedica – executive interview

Webinar: InMed Pharmaceuticals

InMed Pharmaceuticals — Phase II enrolment to begin in second half

InMed Pharmaceuticals – Edison Open House interview

InMed Pharmaceuticals — INM-755 Phase I complete, on to Phase II

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

InMed Pharmaceuticals — INM-755 trial full enrollment expected this quarter

Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

InMed Pharmaceuticals — Developing cannabinol (CBN)

InMed Pharmaceuticals — CTA filed on schedule

InMed Pharmaceuticals — INM-755 getting closer to the clinic

Executive interview – InMed Pharmaceuticals

InMed Pharmaceuticals — Fiscal Q319 results

InMed Pharmaceuticals — Entering the clinic by the end of the year

InMed Pharmaceuticals — Biosynthesis and INM-750 Progress on Track

InMed Pharmaceuticals — Progressing their programs

InMed Pharmaceuticals — Innovating cannabinoids

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide